Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Christopher R. Gibson, Ping Lu, Cheri Maciolek, Christen Wudarski, Zoe Barter, Karen Rowland-Yeo, Mark Stroh, Eseng Lai & Deborah A. Nicoll-Griffith. (2013) Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans. Xenobiotica 43:12, pages 1027-1036.
Read now
Read now
Jennifer B Dressman, Kirstin Thelen & Stefan Willmann. (2011) An update on computational oral absorption simulation. Expert Opinion on Drug Metabolism & Toxicology 7:11, pages 1345-1364.
Read now
Read now
Andrea N Edginton & Ghanashyam Joshi. (2011) Have physiologically-based pharmacokinetic models delivered?. Expert Opinion on Drug Metabolism & Toxicology 7:8, pages 929-934.
Read now
Read now
Articles from other publishers (16)
Yuki Yamaguchi, Takeshi Akiyoshi, Go Kawamura, Ayuko Imaoka, Mitsue Miyazaki, F. Peter Guengerich, Katsunori Nakamura, Koujirou Yamamoto & Hisakazu Ohtani. (2021) Comparison of the inhibitory effects of azole antifungals on cytochrome P450 3A4 genetic variants. Drug Metabolism and Pharmacokinetics 38, pages 100384.
Crossref
Crossref
Yuki Matsumoto, Tamara Cabalu, Punam Sandhu, Georgy Hartmann, Takashi Iwasa, Hiroyuki Yoshitsugu, Christopher Gibson & Naoto Uemura. (2018) Application of Physiologically Based Pharmacokinetic Modeling to Predict Pharmacokinetics in Healthy Japanese Subjects. Clinical Pharmacology & Therapeutics 105:4, pages 1018-1030.
Crossref
Crossref
Michael B. Bolger, Joyce S. Macwan, Muhammad Sarfraz, May Almukainzi & Raimar Löbenberg. (2019) The Irrelevance of In Vitro Dissolution in Setting Product Specifications for Drugs Like Dextromethorphan That are Subject to Lysosomal Trapping. Journal of Pharmaceutical Sciences 108:1, pages 268-278.
Crossref
Crossref
Filippos Kesisoglou, John Chung, Judith van Asperen & Tycho Heimbach. (2016) Physiologically Based Absorption Modeling to Impact Biopharmaceutics and Formulation Strategies in Drug Development—Industry Case Studies. Journal of Pharmaceutical Sciences 105:9, pages 2723-2734.
Crossref
Crossref
Filippos Kesisoglou & Amitava Mitra. (2015) Application of Absorption Modeling in Rational Design of Drug Product Under Quality-by-Design Paradigm. The AAPS Journal 17:5, pages 1224-1236.
Crossref
Crossref
Khaled Abduljalil, Theresa Cain, Helen Humphries & Amin Rostami-Hodjegan. (2014) Deciding on Success Criteria for Predictability of Pharmacokinetic Parameters from In Vitro Studies: An Analysis Based on In Vivo Observations. Drug Metabolism and Disposition 42:9, pages 1478-1484.
Crossref
Crossref
Linda S. Birnbaum & Michael DeVito. 2013. Computational Toxicology. Computational Toxicology
ix
xiv
.
A Rostami-Hodjegan. (2012) Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology. Clinical Pharmacology & Therapeutics 92:1, pages 50-61.
Crossref
Crossref
Peng Zou, Yanke Yu, Nan Zheng, Yongsheng Yang, Hayley J. Paholak, Lawrence X. Yu & Duxin Sun. (2012) Applications of Human Pharmacokinetic Prediction in First-in-Human Dose Estimation. The AAPS Journal 14:2, pages 262-281.
Crossref
Crossref
Md L T Vieira, P Zhao, E G Berglund, K S Reynolds, L Zhang, L J Lesko & S-M Huang. (2012) Predicting Drug Interaction Potential With a Physiologically Based Pharmacokinetic Model: A Case Study of Telithromycin, a Time-Dependent CYP3A Inhibitor. Clinical Pharmacology & Therapeutics 91:4, pages 700-708.
Crossref
Crossref
Christopher L. Shaffer, Renato J. Scialis, Haojing Rong & R. Scott Obach. (2012) Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse events. Biopharmaceutics & Drug Disposition 33:2, pages 72-84.
Crossref
Crossref
Patrick Poulin, Rhys D.O. Jones, Hannah M. Jones, Christopher R. Gibson, Malcolm Rowland, Jenny Y. Chien, Barbara J. Ring, Kimberly K. Adkison, M. Sherry Ku, Handan He, Ragini Vuppugalla, Punit Marathe, Volker Fischer, Sandeep Dutta, Vikash K. Sinha, Thorir Björnsson, Thierry Lavé & James W.T. Yates. (2011) PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach. Journal of Pharmaceutical Sciences 100:10, pages 4127-4157.
Crossref
Crossref
David Wexler & Kirk M. Bertelsen. (2013) A Brief Survey of First‐in‐Human Studies. The Journal of Clinical Pharmacology 51:7, pages 988-993.
Crossref
Crossref
Malcolm RowlandCarl Peck & Geoffrey Tucker. (2011) Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science. Annual Review of Pharmacology and Toxicology 51:1, pages 45-73.
Crossref
Crossref
Qiong Zhou, Zhijie Zheng, Bijun Xia, Lan Tang, Chang Lv, Wei Liu, Zhongqiu Liu & Ming Hu. (2010) Use of Isoform-Specific UGT Metabolism to Determine and Describe Rates and Profiles of Glucuronidation of Wogonin and Oroxylin A by Human Liver and Intestinal Microsomes. Pharmaceutical Research 27:8, pages 1568-1583.
Crossref
Crossref
Tycho Heimbach, Suresh B. Lakshminarayana, Wenyu Hu & Handan He. (2009) Practical Anticipation of Human Efficacious Doses and Pharmacokinetics Using In Vitro and Preclinical In Vivo Data. The AAPS Journal 11:3.
Crossref
Crossref